Table IV.
Characteristics of four patients with biochemical failure.
| Age (years) | Initial PSA (ng/ml) | Gleason score | Clinical T stage | Risk groupa | Neoadjuvant ADT | Time to biochemical failure (months) |
|---|---|---|---|---|---|---|
| 62 | 33.6 | 4+4 | 2b | High | Administered | 30.1 |
| 72 | 12.5 | 4+4 | 2b | High | Administered | 22.2 |
| 67 | 54.9 | 4+3 | 3b | Very high | Administered | 14.8 |
| 75 | 17.2 | 5+4 | 2a | High | Administered | 18.3 |
a
Risk group was categorized using the national comprehensive cancer network risk group classification. PSA, prostate-specific antigen; ADT, androgen deprivation therapy.